Brain Cancer Canada (BCC) is a national, volunteer-driven Canadian charity dedicated to changing outcomes for people living with primary malignant brain tumours, both pediatric and adult. Created in 2015 from a family-led fundraising initiative, the organization now operates as a national funder, channeling donations from individuals, families, and corporate partners into high-impact research and neurosurgical technologies across Canada.
Role of Brain Cancer Canada in the funding ecosystem
BCC focuses its financial support on three main areas: basic, translational and clinical research on brain cancer; acquisition and development of neurosurgical technologies; and projects that can directly improve standards of care and patient access to innovative treatments. It issues formal Requests for Proposals (RFPs) for research and neuro-technology funding and invites scientists, researchers, clinicians and industry partners to apply for support.
The charity’s Scientific Advisory Committee (SAC) is a standing body that manages the distribution of funds to research and technology projects aligned with BCC’s mission. The SAC develops and communicates grant opportunities, receives and evaluates proposals, and submits funding recommendations to the Board of Directors for approval. This structure positions BCC as a recognized grant provider in the Canadian brain cancer research ecosystem.
Grant programs and funded projects
Through its RFPs and targeted awards, Brain Cancer Canada supports projects that address unmet needs in brain cancer, including glioblastoma, diffuse intrinsic pontine glioma (DIPG), medulloblastoma and other aggressive tumour types. The organization highlights numerous competitive awards, such as:
- Research grants of $68K–$100K for clinical trials, novel immunotherapies and gene therapies.
- The Dwayne Andrews Glioblastoma Research Grant, funded by a major corporate donation.
- Multiple $85K project grants focused on recurrent glioblastoma, microRNA research, and immunotherapeutic targets for recurrent medulloblastoma.
Since 2015, BCC reports having raised more than $3 million and directed funding to at least 25 research and technology initiatives nationwide, illustrating a sustained and growing grant portfolio.
General approach to evaluation and impact
While detailed scoring criteria are contained in downloadable RFP packages, the site indicates that Brain Cancer Canada prioritizes projects that advance science, bring promising treatments to Canada, and improve patient access to drugs, combined treatment modalities, and neurosurgical technologies. The SAC evaluates proposals for scientific merit, potential impact on outcomes, and alignment with identified gaps in brain cancer care.
BCC publishes annual impact reports outlining how community fundraising is translated into grants, investments per year, and examples of funded projects. Milestone summaries show year-over-year invested amounts and demonstrate transparency about how donor dollars are allocated.
Supported communities and overall impact
Brain Cancer Canada’s funding is designed to benefit both adult and pediatric brain cancer patients. Projects often involve Canadian universities, hospitals, and research institutes working on cutting-edge therapies or technologies. In parallel with research grants, the organization engages in advocacy for better access to treatments and supports patient and caregiver resources.
Through partnerships with founding and corporate sponsors, community fundraising, and volunteer leadership, BCC continues to expand its granting capacity, aiming to close the funding gap for brain cancer research and help transform the standard of care for patients across Canada.